Diabetes Res Clin Pract.docx
- 文档编号:11679807
- 上传时间:2023-03-30
- 格式:DOCX
- 页数:14
- 大小:85.16KB
Diabetes Res Clin Pract.docx
《Diabetes Res Clin Pract.docx》由会员分享,可在线阅读,更多相关《Diabetes Res Clin Pract.docx(14页珍藏版)》请在冰豆网上搜索。
DiabetesResClinPract
DiabetesResClinPract.2014Dec3.pii:
S0168-8227(14)00523-3.doi:
10.1016/j.diabres.2014.11.005.[Epubaheadofprint]
Alpha-lipoicacidmodifiescirculatingangiogenicfactorsinpatientswithtype2diabetesmellitus.
DworackaM1,IskakovaS2,KrzyżagórskaE3,WesołowskaA4,KurmambayevY2,DworackiG5.
Authorinformation
∙1DepartmentofPharmacology,PoznanUniversityofMedicalSciences,Poznań,Poland.Electronicaddress:
mdworac@ump.edu.pl.
∙2DepartmentofPharmacology,WestKazakhstanStateMedicalUniversity,Aktobe,Kazakhstan.
∙3PoznanSpecialistCenterofMedicalCare,DiabetologyOut-patientClinic,Poznań,Poland.
∙4DepartmentofPharmacology,PoznanUniversityofMedicalSciences,Poznań,Poland.
∙5DepartmentofClinicalImmunology,PoznanUniversityofMedicalSciences,Poznań,Poland.
Abstract
AIMS:
Inrecentyearsinteresthasbeenfocusedonangiogenesisasaprocessinvolvedincoronaryarterydisease(CAD)anddiabeticdistalsensorimotorpolyneuropathy(DSPN).Recentstudieshavedemonstratedthepossibleangiogenesis-modulatingpotentialofalpha-lipoicacid(ALA)forDSPNandCAD.TheaimofourstudywastoinvestigatetheinfluenceofALAonserumangiogenicfactorsinpatientswithDM-2(type2diabetes)withCADandDSPN.
METHODS:
Sixtypatientswithtype2DM(T2DM)andCADand25non-diabeticsubjectswerestudied.ThirtypatientswithT2DM,CADandDSPNweregiven600mgofALAadayfor90days.VEGF,bFGF,MCP-1,angiogenin,IL-12andIL-10concentrationsintheseraweremeasuredbyflowcytometry.
RESULTS:
ALAsignificantlyincreasedVEGF,bFGFandIL-10anddecreasedMCP-1serumconcentrationsinpatientswithT2DMandCADandDSPN.VEGFandIL-10serumlevels,bothbeforeandafterALA-treatment,werehigherinthisgroupthaninT2DMandCADpatients,whilecirculatingbFGFwashigherandMCP-1serumlevellowerinpatientswithT2DMandCADandDSPNonlyinthepost-ALA-treatment,comparedtotheT2DMandCADgroup.
CONCLUSIONS:
ALAmayinfluenceangiogenesisintype2diabeticpatientsthroughaneffectonsomecirculatingfactorsincludingVEGF,bFGF,MCP-1andIL-10.
Copyright©2014ElsevierIrelandLtd.Allrightsreserved.
KEYWORDS:
Alpha-lipoicacid;IL-10;MCP-1;Type2diabetes;VEGF;bFGF
∙Abstract
Format
∙
Summary
∙
Summary(text)
∙
Abstract
∙
Abstract(text)
∙
MEDLINE
∙
XML
∙
PMIDList
Apply
Sendto:
ChooseDestination
∙
File
∙
Clipboard
∙
Collections
∙
∙
Order
∙
MyBibliography
∙
Citationmanager
∙Format
CreateFile
∙1selecteditem:
25535146
∙Format
MeSHandOtherData
∙Subject
∙Additionaltext
∙
Didn'tgetthemessage?
Findoutwhy...
AddtoClipboard
AddtoCollections
Orderarticles
AddtoMyBibliography
Generateafileforusewithexternalcitationmanagementsoftware.
CreateFile
SeecommentinPubMedCommonsbelow
EurRevMedPharmacolSci.2014Dec;18(23):
3715-9.
α-Lipoicacidtreatmentofagedtype2diabetesmellituscomplicatedwithacutecerebralinfarction.
ZhaoL1,HuFX.
Authorinformation
∙1DepartmentofEndocrinology,HedongDistrictPeople'sHospital,Linyi,China.liangzhaocn@.
Abstract
OBJECTIVE:
Thisstudyaimstoevaluatetheefficacyandsafetyofα-lipoicacidinthetreatmentofagedtype2diabetesmellitus(T2DM)complicatedwithacutecerebralinfarction.
PATIENTSANDMETHODS:
90patientswererandomlydividedintotwogroups,onthebasisofconventionaltreatment.Theexperimentgroupwasadministratedwithα-lipoicacid,whileonlyVitaminCforthecontrolgroup,for3consecutiveweeks.Beforeandaftertheexperiment,superoxidedismutase(SOD),glutathioneperoxidase(GSH-Px)andmalondialdehyde(MDA)levelsweremeasuredandscoredwiththeNIHSS(NationalInstitutesofHealthStrokeScale),andthechangesofbloodglucose,insulinfunctionandotherindicatorswereobserved.
RESULTS:
Afterthetreatment,theplasmaSODandGSH-Pxlevelsincreased,whileMDAdecreased(p<0.05),withstatisticalsignificancewhencomparedwiththecontrolgroup(p<0.01).NIHSSscore,bloodglucose,bloodlipidsandHOMA-IAoftheexperimentgroupdecreasedsignificantly(p<0.01);andnosignificantadversereactionswerefoundinbothgroups.
CONCLUSIONS:
α-lipoicacidwassafeandeffectiveinthetreatmentofagedT2DMcomplicatedwithacutecerebralinfarction,significantlyreducingthepatient'soxidativestress,bloodglucoseandlipidlevelsandbeingabletoimproveisletfunction.
Efficacyofα-lipoicacidindiabeticneuropathy.
PapanasN1,ZieglerD.
Authorinformation
∙1DemocritusUniversityofThrace,SecondDepartmentofInternalMedicine,Alexandroupolis,Greece.
Abstract
INTRODUCTION:
Neuropathyisaseriouscomplicationofdiabetes.Itsmanagementfocusesonglycaemiccontrol,multifactorialcardiovascularriskintervention,pathogenesis-orientedtherapy,andanalgesicswhereneeded.
AREASCOVERED:
Theobjectiveofthisreviewisassessmentofefficacyandsafetyofαlipoicacid(ALA,alsothiocticacid)inpathogenesis-orientedtreatmentofdiabeticneuropathy.ThemechanismsofactionofALAinexperimentaldiabeticneuropathyincludereductionofoxidativestressalongwithimprovementinnervebloodflow,nerveconductionvelocity,andseveralothermeasuresofnervefunction.Thereisampleevidencefromrandomised,double-blind,placebo-controlledclinicaltrialsandmeta-analyses,suggestingthatALAisefficaciousandsafeforthediabeticneuropathy,accomplishingclinicallymeaningfulimprovements.
EXPERTOPINION:
ALAisavaluabletherapeuticoptionfordiabeticneuropathy.Whencomparedwithcurrentlylicensedanalgesicdrugs,itisbettertolerated,hasamorerapidonsetofaction,andimprovesparaesthesiae,numbness,sensorydeficits,andmusclestrengthinadditiontoneuropathicpain.Inclinicalpractice,ALAmaybechoseninpatientswithearlyneuropathicdeficitsandsymptoms,inwhomclinicalimprovementismorelikely.ALAshouldalsobeconsideredwhencomorbiditiesrenderotheranalgesicslessappropriateorinthepresenceofcardiovascularautonomicneuropathy.
KEYWORDS:
diabetesmellitus;diabeticneuropathy;efficacy;oxidativestress;thiocticacid;treatment
Alpha-lipoicacidasapleiotropiccompoundwithpotentialtherapeuticuseindiabetesandotherchronicdiseases.
GomesMB1,NegratoCA2.
Authorinformation
∙1DepartmentofInternalMedicine,DiabetesUnit,StateUniversityHospitalofRiodeJaneiro,Avenida28deSetembro,77,3°andar,CEP20.551-030RiodeJaneiro,Brazil.
∙2DepartmentofInternalMedicine,Bauru'sDiabeticsAssociation,17012-433Bauru,SãoPaulo,Brazil.
Abstract
Alpha-lipoicacidisanaturallyoccurringsubstance,essentialforthefunctionofdifferentenzymesthattakepartinmitochondria'soxidativemetabolism.Itisbelievedthatalpha-lipoicacidoritsreducedform,dihydrolipoicacidhavemanybiochemicalfunctionsactingasbiologicalantioxidants,asmetalchelators,reducersoftheoxidizedformsofotherantioxidantagentssuchasvitaminCandE,andmodulatorofthesignalingtransductionofseveralpathways.Theseabove-mentionedactionshavebeenshowninexperimentalstudiesemphasizingtheuseofalpha-lipoicacidasapotentialtherapeuticagentformanychronicdiseaseswithgreatepidemiologicalaswelleconomicandsocialimpactsuchasbraindiseasesandcognitivedysfunctionslikeAlzheimerdisease,obesity,nonalcoholicfattyliverdisease,burningmouthsyndrome,cardiovasculardisease,hypertension,sometypesofcancer,glaucomaandosteoporosis.Manyconflictingdatahavebeenfoundconcerningtheclinicaluseofalpha-lipoicacidinthetreatmentofdiabetesandofdiabetes-relatedchroniccomplicationssuchasretinopathy,nephropathy,neuropathy,woundhealinganddiabeticcardiovascularautonomicneuropathy.Themostfrequentclinicalconditioninwhichalpha-lipoicacidhasbeenstudiedwasinthemanagementofdiabeticperipheralneuropathyinpatientswithtype1aswelltype2diabetes.Consideringthatoxidativestress,aimbalancebetweenproandantioxidantswithexcessiveproductionofreactiveoxygenspecies,isafactorinthedevelopmentofmanydiseasesandthatalpha-lipoicacid,anaturalthiolantioxidant,hasbeenshowntohavebeneficialeffectsonoxidativestressparametersinvarioustissueswewrotethisarticleinordertomakeanup-to-datereviewofcurrentthinkingregardingalpha-lipoicacidanditsuseasanantioxidantdrugtherapyforamyriadofdiseasesthatcouldhavepotentialbenefitsfromitsuse.
KEYWORDS:
Alpha-lipoicacid;Biochemicalaction;Chronicdiseases;Diabetesmellitus
JDiabetesComplications.2015Jan-Feb;29
(1):
64-7.doi:
10.1016/j.jdiacomp.2014.09.011.Epub2014Sep30.
Thealpha-lipoicaciddecreasesurinarypodocalyxinexcretionintype2diabeticsbyinhibitingoxidativestressinvivo.
LinH1,YeS2,XuJ3,WangW3.
Authorinformation
∙1DepartmentofEndocrinology,AnhuiProvincialHospitalAffiliatedtoAnhuiMedicalUniversity,Hefei,Anhui,China;DepartmentofInternalMedicine,MaanshanMaternalandChildHealthCareCenter,Maanshan,Anhui,China.
∙2DepartmentofEndocrinology,AnhuiProvincialHospitalAffiliatedtoAnhuiMedicalUniversity,Hefei,Anhui,China.Electronicaddress:
ysd6406@.
∙3DepartmentofEndocrinology,AnhuiProvincialHospitalAffiliatedtoAnhuiMedicalUniversity,Hefei,Anhui,China.
Abstract
OBJECTIVE:
ToobservetheeffectsofAlpha-lipoicacid(ALA)onoxidativestress(OS)invivoandurinarypodocalyxin(PCX,theglomerularpodocytemarkerprotein)excretionintype2diabeticsandexploreitspossibleprotectivemechanismsonglomerularpodocytes.
METHODS:
Thirty
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- Diabetes Res Clin Pract